Rakovina and Celvion AI Identify Two Cancer Indications for ATR Inhibitor
Rakovina and Celvion say an AI analysis identified two priority cancer indications for an ATR inhibitor.
Related stories
Taiwan's Taiex Falls 3.0% to 44983.64
M impact | EQUITY | Oct 30, 2026, 02:03 AM UTC
SAIC Motor Shares Fall 5.9% as Q3 Profit Plunges
SAIC Motor shares fell 5.9% in early trading to a two-month low. The automaker reported third-quarter net profit on Thursday.
M impact | EQUITY | Oct 30, 2026, 02:03 AM UTC
Boston Scientific Reports Q3 Sales of $5.138 Billion, Lowers 2026 EPS Guidance
Boston Scientific reported Q3 2026 sales of $5.138 billion, up 1.5% year over year, and adjusted EPS of $0.73. It lowered full-year adjusted EPS guidance to $3.16–$3.18, citing Chi
M impact | EQUITY | Oct 30, 2026, 02:02 AM UTC
Indonesia's Benchmark Stock Index Falls 0.9% to 5,054.729
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC
Welspun Corp Q2 Net Profit Rises 3%, Plans Rs 2,280 Crore Expansion
Welspun Corp reported a 3% rise in Q2 net profit. Revenue from operations was Rs 4,644 crore. It cleared investments of up to Rs 2,280 crore across the US and Jordan; US capacity i
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC
Milky Mist Q2 Net Profit Nearly Triples as Revenue Tops ₹1,000 Crore
Milky Mist Dairy Food reported Q2 FY27 revenue from operations of ₹1,089.4 crore, up 41.6% year on year. The supplied report says net profit nearly tripled.
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC